Painful multifocal arthritis: therapy with rhenium 186 hydroxyethylidenediphosphonate ((186)Re HEDP) after failed treatment with medication--initial results of a prospective study.
Eight patients (77 joints) with polyarthritis were treated systemically with 570 MBq (15.4 mCi) of rhenium 186 ((186)Re) hydroxyethylidenediphosphonate (HEDP). Pain and disease activity were assessed monthly. In six (75%) of eight patients, a single injection of (186)Re HEDP led to an improvement in disease activity. Systemic low-dose treatment with (186)Re HEDP can reduce pain and disease activity in patients with polyarthritis.
Palmedo
H
H
Department of Nuclear Medicine, University of Bonn, Sigmund-Freud-Strasse 25, 53105 Bonn, Germany. palmedo@mailer.med.uni-bonn.de
Rockstroh
J K
JK
Bangard
M
M
Schliefer
K
K
Risse
J
J
Menzel
C
C
Biersack
H J
HJ
D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000532:radiotherapy*; D012968:Etidronic Acid / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds; D010146:Pain / Q000188:drug therapy; D059408:Pain Management; D011446:Prospective Studies; D011868:Radioisotopes / Q000627:therapeutic use*; D012211:Rhenium / Q000627:therapeutic use*; D017211:Treatment Failure
D009942:Organometallic Compounds; D011868:Radioisotopes; C101598:rhenium-186 HEDP; D012211:Rhenium; D012968:Etidronic Acid